# Allergan Aesthetics an AbbVie Company

> Allergan Aesthetics is AbbVie’s global medical aesthetics business, developing and selling injectables, body contouring systems, surgical products, and skincare. Its portfolio includes BOTOX Cosmetic, JUVÉDERM, CoolSculpting, and SkinMedica, supported by provider education, practice services, and the Allē consumer rewards program.

- **Founded:** 2020
- **Headquarters:** Irvine, United States
- **Products:** BOTOX Cosmetic, JUVÉDERM Collection of Fillers, SKINVIVE by JUVÉDERM, CoolSculpting, SkinMedica
- **Notable:** Established as a dedicated AbbVie global aesthetics business in 2020., Reported USD 4.860 billion in global aesthetics portfolio net revenue in FY2025., Received Canadian and European Boey approvals in 2026.

## Products & services

- **BOTOX Cosmetic** — Prescription onabotulinumtoxinA for temporary improvement of specified facial lines and platysma bands in adults under U.S. labeling.
- **JUVÉDERM Collection of Fillers** — Hyaluronic acid injectable formulations for distinct facial aesthetic indications; approvals vary by formulation and market.
- **SKINVIVE by JUVÉDERM** — Hyaluronic acid injectable with U.S. cheek smoothness and, from June 2026, neck-line indications in adults over 21.
- **CoolSculpting** — Noninvasive body contouring devices using controlled cooling for indicated fat bulges.
- **SkinMedica** — Topical skincare sold online and through licensed physicians and medically supervised spas; 2026 launches include Barrier Calming Cream and HA5 Hydra Collagen Facial Mist.
- **Natrelle** — Breast implant portfolio for augmentation and reconstruction, subject to product labeling and surgical risks.
- **DiamondGlow** — Dermabrasion device that also delivers topical cosmetic serums.
- **Allē** — Consumer loyalty program offering points and promotions on eligible treatments and products.
- **Allergan Medical Institute** — Professional medical education and training for aesthetic providers.
- **Allergan Partner Privileges** — Practice portfolio loyalty program updated in August 2026 with savings and growth benefits.
- **Boey** — TrenibotulinumtoxinE, approved in Canada in June 2026 and Europe in July 2026 for specified adult glabellar-line indications; results typically wear off in approximately two to three weeks.
- **AA Signature: SKIN360** — Multimodal consultation approach launched in the U.S. in September 2026, supported by AMI education and portfolio products.

## Achievements

- Established as a dedicated AbbVie global aesthetics business in 2020.
- Reported USD 4.860 billion in global aesthetics portfolio net revenue in FY2025.
- Received Canadian and European Boey approvals in 2026.
- Announced U.S. FDA approval of SKINVIVE for neck appearance in June 2026.

## Latest updates

- **2026-10** — Presented a multimodal treatment education program and eight scientific posters at AMWC Dubai, highlighting HArmonyCa and other portfolio brands.
- **2026-09** — Launched AA Signature: SKIN360 in the U.S.; introduced SkinMedica Barrier Calming Cream at a stated $140 launch price.
- **2026-08** — Refreshed Allergan Partner Privileges; announced FDA acceptance for review of a BOTOX Cosmetic masseter muscle prominence application. Acceptance is not approval.
- **2026-07** — Announced European Commission approval of Boey for a specified adult glabellar-line indication.
- **2026-06** — Announced Health Canada approval of Boey and U.S. FDA approval of a SKINVIVE neck indication.
- **2026-02** — AbbVie reported FY2025 aesthetics portfolio net revenue of $4.860 billion.

## Links

- Website: https://www.allerganaesthetics.com/
- LinkedIn: https://www.linkedin.com/company/allergan-aesthetics/
- YouTube: https://www.youtube.com/allerganaestheticsus
- Instagram: https://www.instagram.com/allerganaesthetics/
- Facebook: https://www.facebook.com/allerganaesthetics/

---

Profile page: https://yespress.io/allergan-aesthetics-an-abbvie-company
Published by YesPress — https://yespress.io
Last updated: 2026-10-25